TY - JOUR T1 - Histopathological findings in COVID-19 cases: A Systematic Review JF - medRxiv DO - 10.1101/2020.10.11.20210849 SP - 2020.10.11.20210849 AU - Hamed Hammoud AU - Ahmed Bendari AU - Tasneem Bendari AU - Iheb Bougmiza Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/16/2020.10.11.20210849.abstract N2 - Background The current COVID-19 pandemic is considered one of the most serious public health crisis over the last few decades. Although the disease can result in diverse, multiorgan pathology, there have been very few studies addressing the postmortem pathological findings of the cases. Active autopsy amid this pandemic could be an essential tool for diagnosis, surveillance, and research.Objective To provide a total picture of the SARS-CoV-2 histopathological features of different body organs through a systematic search of the published literature.Methods A systematic search of electronic databases (PubMed, ScienceDirect, Google scholar, Medrxiv & Biorxiv) was carried out from December 2019 to August, 15th 2020, for journal articles of different study designs reporting postmortem pathological findings in COVID-19 cases. PRISMA guidelines were used for reporting the review.Results A total of 50 articles reporting 430 cases were included in our analysis. Postmortem pathological findings were reported for different body organs, pulmonary system (42 articles), cardiovascular system ( 23 articles), hepatobiliary system (22 articles), kidney (16 articles), spleen, and lymph nodes (12 articles), and central nervous system (7 articles). In lung samples, diffuse alveolar damage (DAD) was the most commonly reported findings in 239 cases (84.4%). Myocardial hypertrophy (87 cases by 51.2%), arteriosclerosis (121 cases by 62%), and steatosis ( 118 cases by 59.3%) were the most commonly reported pathological findings in the heart, kidney, and hepatobiliary system respectively.Conclusion Autopsy examination as an investigation tool could help in a better understanding of SARS-CoV-2 pathophysiology, diagnosis, management, and subsequently improving patient care.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo FundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:It's a systematic review; No need for ethical approval or patient's consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTables https://www.editorialmanager.com/prp/download.aspx?id=124729&guid=0c9e8fd8-0abe-4b95-bd5a-13d27daaf816&scheme=1 appendix 1 https://www.editorialmanager.com/prp/download.aspx?id=124731&guid=f8ebb7b6-363d-4636-8d76-8e20816f49da&scheme=1 Appendix 2 https://www.editorialmanager.com/prp/download.aspx?id=124732&guid=7cb1ad8e-32fb-4aec-97b6-c8606d7583d0&scheme=1 Appendix 3 https://www.editorialmanager.com/prp/download.aspx?id=124733&guid=e2671aff-6beb-4d7e-81dc-6505e413768a&scheme=1 Appendix 4 https://www.editorialmanager.com/prp/download.aspx?id=124734&guid=e1be8ed9-9d68-4026-b781-6f4c071f11eb&scheme=1 ER -